GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (NAS:ABUS) » Definitions » 3-Year Revenue Growth Rate

Arbutus Biopharma (Arbutus Biopharma) 3-Year Revenue Growth Rate : 6.20% (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Arbutus Biopharma 3-Year Revenue Growth Rate?

Arbutus Biopharma's Revenue per Share for the three months ended in Mar. 2024 was $0.01.

During the past 12 months, Arbutus Biopharma's average Revenue per Share Growth Rate was -63.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 6.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 8.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was -15.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Arbutus Biopharma was 237.10% per year. The lowest was -69.70% per year. And the median was -1.30% per year.


Competitive Comparison of Arbutus Biopharma's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Arbutus Biopharma's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's 3-Year Revenue Growth Rate falls into.



Arbutus Biopharma 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Arbutus Biopharma  (NAS:ABUS) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Arbutus Biopharma 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Arbutus Biopharma (Arbutus Biopharma) Business Description

Traded in Other Exchanges
Address
701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Executives
Melissa Rewolinski director 9000 STATE ROAD, PHILADELPHIA PA 19136
Karen Sims officer: Chief Medical Officer 701 VETERANS CIRCLE, WARMINSTER PA 18974
J. Christopher Naftzger officer: General Counsel and CCO 633 LOWTHER ROAD, LEWISBERRY PA 17339
Michael J. Sofia officer: Chief Scientific Officer C/O ARBUTUS BIOPHARMA CORP., SUITE 100, 8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Tram Tran director C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Michael J. Mcelhaugh officer: Chief Business Officer C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
James R Meyers director GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew Cheng director 170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
William H. Collier director, officer: President and CEO C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Elizabeth Howard officer: Executive VP & General Counsel 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
David C Hastings officer: Chief Financial Officer C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Gaston Picchio officer: Chief Development Officer C/O ARBUTUS BIOPHARMA CORP, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8

Arbutus Biopharma (Arbutus Biopharma) Headlines